Table 2.
Demographic and Clinical Characteristics of Clinical Trial Participants (n = 10).
| Median age, years (minimum-maximum) | 64.4 (47-81) |
|---|---|
| Race | n (%) |
| White | 7 (70%) |
| Black/African American | 1 (10%) |
| Hispanic | 1 (10%) |
| More than 1 race | 1 (10%) |
| Employment | |
| Full-time | 2 (20%) |
| Part-time | 2 (20%) |
| Not currently employed | 6 (60%) |
| Gender | |
| Male | 1 (10%) |
| Female | 9 (90%) |
| Type of cancer | |
| Ovarian | 1 (10%) |
| Breast | 5 (50%) |
| Colon | 2 (20%) |
| Uterine | 1 (10%) |
| Bladder | 1 (10%) |
| Stage of cancer | |
| Stage I | 1 (10%) |
| Stage II | 2 (20%) |
| Stage III | 5 (50%) |
| Uncertain | 2 (20%) |
| Last dose of chemotherapy | |
| <6 Months | 4 (40%) |
| <5 Years | 3 (30%) |
| 5 + Years | 3 (30%) |
| Patient Neurotoxicity Questionnaire (PNQ) sensory symptoms | |
| No numbness, pain, or tingling | 0 (0%) |
| Mild numbness, pain, and tingling | 0 (0%) |
| Moderate numbness, pain, and tingling | 4 (40%) |
| Moderate to severe numbness, pain, and tingling | 6 (60%) |
| Weakness symptoms | |
| No perceived weakness | 1 (10%) |
| Mild weakness | 1 (10%) |
| Moderate weakness | 3 (30%) |
| Moderate to severe weakness | 5 (50%) |